GlaxoSmithKline (GSK) reported a 2% year-over-year decline in third-quarter sales, driven by a significant drop in vaccine revenue. However, the company’s specialty medicine division experienced strong growth, offsetting the impact of lower vaccine sales. GSK also reaffirmed its 2024 financial guidance, despite revising downward its outlook for vaccine sales.